The Conversation (0)
Trillium Therapeutics announced the presentation of new clinical data from its ongoing phase 1 a/b trials for their CD47-blocking agents, TTI-621.
Trillium Therapeutics (NASDAQ:TRIL; TSX:TRIL) announced the presentation of new clinical data from its ongoing phase 1 a/b trials for their CD47-blocking agents, TTI-621, at the annual meeting for the American Society of Hematology.
As quoted in the press release:
Poster Presentation 4076: A Single Direct Intratumoral Injection of TTI-621 (SIRPaFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal. Presenter: Christiane Querfeld, MD, PhD, City of Hope National Medical Center.
This poster presentation highlighted preliminary safety and anti-tumor activity of intratumoral TTI-621 administration in highly pretreated patients with relapsed or refractory mycosis fungoides or Sézary syndrome. Intratumoral injection was well tolerated, with no dose-limiting toxicity observed. A rapid reduction in CAILS scores, which measures local lesion responses, was observed in 9 out of 10 mycosis fungoides patients and a reduction in circulating leukemic Sézary cells was observed in 3 out of 3 patients. Several patient profiles were presented which demonstrate clinical responses in disfiguring lesions, in some cases after a single dose of TTI-621. Collectively, the data demonstrate that cutaneous T-cell lymphoma (CTCL) appears biologically responsive to intratumoral injections of TTI-621, and enrollment in this trial (NCT02890368) is continuing.
Poster Presentation 4116: TTI-621 (SIRPaFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL). Presenter: Stephen Ansell, MD, PhD, Division of Hematology, Mayo Clinic.
Click here to read the full press release.
Source: www.marketwired.com